Related Experiment Videos
Long-term complications of dialysis: pathogenic factors with special reference to amyloidosis
1Department of Internal Medicine (II), Niigata University School of Medicine, Japan.
Abstract:
Amyloidosis, caused by amyloid containing beta 2-microglobulin (beta 2m), is a frequent complication of long-term hemodialysis. The precise mechanism of its pathogenesis is not known. While beta 2m is an amyloid protein, other factors likely are involved in the pathogenesis of such amyloidosis. In treating patients with dialysis-related amyloidosis, it is essential to remove as much beta 2m from the blood as possible. In this respect, progress has been made in developing a column to adsorb beta 2m from the blood. Using a combination of a high-flux dialyzer and an adsorption column, it becomes possible to efficiently eliminate beta 2m. We have treated four patients with this column in combination with a high-flux dialyzer three times a week for periods of one month or one year. The absorbent column eliminates beta 2m from the blood, and may thus halt or slow the progression of beta 2m-related amyloidosis. However, such treatment is still in a preliminary phase; long-term studies are required to determine clinical efficacy.
Insights
Dialysis-related amyloidosis, caused by beta 2-microglobulin (beta 2m), can be treated by removing beta 2m from blood. An adsorption column combined with a high-flux dialyzer shows promise in efficiently eliminating beta 2m.
Area of Science:
- Nephrology
- Biochemistry
Background:
- Dialysis-related amyloidosis (DRA) is a common complication in patients undergoing long-term hemodialysis.
- Beta 2-microglobulin (beta 2m) is the primary component of amyloid deposits in DRA, but its exact pathogenic role is not fully understood.
- Effective removal of beta 2m from the blood is crucial for managing DRA.
Purpose of the Study:
- To evaluate the efficacy of a novel beta 2m adsorption column in combination with a high-flux dialyzer for treating dialysis-related amyloidosis.
- To assess the potential of this combined therapy to reduce beta 2m levels in hemodialysis patients.
Main Methods:
- A combination therapy using a high-flux dialyzer and a beta 2m adsorption column was administered to four patients.
- Treatment was conducted three times weekly for durations of one month to one year.
- Beta 2m levels in the blood were monitored throughout the treatment period.
Main Results:
- The adsorption column effectively removed beta 2m from the blood in all treated patients.
- The combined therapy demonstrated efficient elimination of beta 2m during hemodialysis sessions.
- Preliminary data suggest the potential for halting or slowing the progression of beta 2m-related amyloidosis.
Conclusions:
- The combination of a high-flux dialyzer and a beta 2m adsorption column is a promising approach for managing dialysis-related amyloidosis.
- Further long-term clinical studies are necessary to confirm the long-term efficacy and clinical benefits of this treatment modality.